Title: Awareness and perceptions among members of a 1 Japanese cancer patient advocacy group concerning the 2 financial relationships between the pharmaceutical industry 3 and physicians: a mixed-methods analysis of survey data 4 5 Running head: Japanese patient perception on financial relationship 6 7 **Authors** 8 Anju Murayama, ^{1,†}, * Yuki Senoo, ^{1,†} Kayo Harada, ^{1,†} Yasuhiro Kotera, ² Hiroaki Saito, ³ 9 Toyoaki Sawano, 4 Yosuke Suzuki, 1 Tetsuya Tanimoto, 1,5 Akihiko Ozaki 6 10 † Equally contributed to the work. 11 * Corresponding author 12 13 14 **Affiliations** ¹ Medical Governance Research Institute, Minato-ku, Tokyo, Japan 15 16 ² Human Sciences Research Centre, University of Derby, Derby, Derbyshire, United 17 Kingdom ³ Department of Gastroenterology, Sendai Kousei Hospital, Sendai, Miyagi, Japan 18 ⁴ Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima, 19 20 Japan ⁵ Department of Internal Medicine, Navitas Clinic Kawasaki, Tokyo, Japan 21 ⁶ Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, 22 23 Fukushima, Japan 24 25 **Corresponding author** Anju Murayama, Medical Governance Research Institute, Minato-ku, Tokyo, Japan 26 27 Email address: ange21tera@gmail.com Telephone: 81-90-6321-6996 28 29 30 **Conflicts of interest** 31 Dr. Saito receives personal fees from Taiho Pharmaceutical Co., Ltd. outside the scope of 32 the submitted work. Dr. Ozaki receives personal fees from Medical Network Systems 33 outside the scope of the submitted work. Dr. Tanimoto receives personal fees from 1

34 Medical Network Systems and Bionics Co. Ltd. outside the scope of the submitted work. 35 The remaining authors declare no conflicts of interest. 36 37 **Funding** 38 This study was funded in part by the Medical Governance Research Institute. This 39 non-profit enterprise receives donations from pharmaceutical companies, including Ain 40 Pharmaciez, Inc., other organizations, and private individuals. This study also received 41 support from the Waseda Chronicle, an independent non-profit news organization 42 dedicated to investigative journalism. 43 44 **Keywords** 45 conflict of interest, ethics, Japan, financial relationship, patient-centered care, 46 pharmaceutical industry

48 Abstract (247 words) 49 **Objectives** 50 Financial conflicts of interest (FCOI) between pharmaceutical companies (Pharma) and 51 healthcare domains may unduly influence physician-led clinical practice and 52 patient-centered care. However, the extent of awareness and perceptions of FCOI among 53 Japanese cancer patients remains unclear. This study aimed to assess these factors and 54 their impacts on physician trustworthiness among Japanese cancer patients. 55 56 Methods 57 A cross-sectional study using self-administered surveys was conducted on a Japanese 58 cancer patient advocacy group with 800 registered members from January to February 59 2019. Main outcome measures included awareness and perceptions of physician-Pharma 60 interactions, their impact on physician trustworthiness, and attitudes towards FCOI 61 among professions. We also performed thematic analyses on additional comments 62 responders provided in the surveys. 63

64 **Results** 65 Among the 524 invited members, 96 (18.3%) completed the questionnaire. Of these, 69 66 (77.5%) were cancer patients. The proportion of participants aware of such interactions 67 ranged from 2.1% to 65.3%, depending on the interaction type. Participants were 68 generally neutral on how the interactions would affect physician trustworthiness. A large 69 proportion of participants agreed that these interactions were unethical, could influence 70 physicians' prescribing behavior leading to unnecessary prescriptions, and negatively 71 affect physician trustworthiness. Qualitative responses (n=56) indicated that patients 72 expected physicians to use sound ethical judgment and avoid accepting incentives. 73 Participants were also concerned about their treatment and the undue influence of FCOI 74 on physicians. 75 76 Conclusion 77 Most participants were aware of at least one FCOI between Pharma and physicians and 78 perceived them negatively. Further efforts to regulate FCOI appear necessary to protect 79 patient-centered care.

- 80 **Abbreviations:**
- 81 FCOI: Financial conflicts of interest; United States (US); Pharma: Pharmaceutical
- 82 companies

Main text

83

84

Introduction

85 In recent years, patient-centered care has widely been considered a key component of 86 healthcare delivery. Defined as one of the Six Domains of Healthcare Quality introduced 87 by the National Academy of Medicine,[1] patient-centered care focuses on delivering 88 healthcare respecting patient preferences, needs, and values. Therefore, financial 89 conflicts of interest (FCOI) between pharmaceutical companies (Pharma) and healthcare 90 domains are of significant concern, mainly due to potential bias in patient care and 91 medical institutions' operation.[2-6] Key criteria of patient-centered care include full 92 transparency and fast delivery of information. [7-9] In the world today, there are 93 transparency initiatives such as the Sunshine Act and Open Payments Database in the 94 United States (US),[10-12] Transparency in Healthcare in France,[5] Euro for Doctors 95 and LeitlinienWatch in Germany,[13, 14] Disclosure UK in the United Kingdom,[15-17] 96 Disclosure Australia in Australia, [18, 19] and Money Database in Japan, [2, 20, 21], all of 97 which emphasize improving transparency and raising awareness of FCOI among patients 98 and the general public to achieve excellent patient-centered care.

However, there remains an ongoing controversy about whether these transparency initiatives improve the general awareness of FCOI.[10, 12, 22] A previous qualitative study conducted before these initiatives reported that most cancer clinical trial participants had a positive or neutral view of physicians receiving research funding from Pharma. [23] Moreover, there has been little improvement in awareness of FCOI even after the launch of transparency initiatives. [10, 22, 24] Rather, it has been reported that public trust in healthcare professionals dropped following the launch of these initiatives.[25] These findings demonstrate the limited effect on the awareness of FCOI by these transparency initiatives. Nonetheless, recent discussions on this issue have not considered specific populations with a higher interest in this topic, including patients with critical illnesses or their caregivers. Among patient populations, cancer patients are particularly important, given the critical nature of the disease and its burden, [26] as well as the development of numerous novel and expensive therapeutics.[27, 28] Since novel anticancer drugs are

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

potentially highly profitable, these agents' development remains among Pharma's highest priorities.[29] Therefore, these findings suggest the importance for cancer patients to understand FCOI among Pharma and healthcare domains. The issues surrounding FCOI are of particular relevance in Japan due to its universal health coverage and the fact that its pharmaceutical market is the third-largest globally, after the US and China.[30] In 2018, anticancer drugs' annual pharmaceutical sales exceeded 1.24 trillion Japanese yen (JPY; 11 billion US dollars [USD]), accounting for 12% of Japan's total annual pharmaceutical sales. Despite an overall decline in Japan's pharmaceutical sales, the oncology drug market continues to expand and is projected to exceed 13 billion USD by 2025.[31] There also has been progress in terms of Japanese transparency initiatives. Along with several non-profit organizations, the Japan Pharmaceutical Manufacturer Association has, since it first developed transparency guidelines in 2011,[32] led efforts to improve transparency in Pharma and healthcare domains' financial relationships. For instance, since 2013, all Japan Pharmaceutical Manufacturer Association members have voluntarily disclosed payments to physicians

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

on their respective websites following established transparency guidelines.[32] Also, Japanese non-profit organizations, including the Medical Governance Research Institute and Waseda Chronicle, have developed the Money Database. This database enables the general public to learn about financial relationships among individual pharmaceutical companies and healthcare sectors.[2, 33-36] While these organizations disclose information regarding industry payments made to physicians, how Japanese cancer patients perceive the information remains unclear. In sum, the present study's purpose was to examine awareness of physician-Pharma interactions and their impact on physicians' trust while also appraising perceptions of these payments among Japanese cancer patients. **Methods:** Study setting, design, and participants The study population consisted of 524 individuals of the Cancer Treatment Society for Citizens, a support group for cancer patients established in 2004 with 800 registered

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

members. In response to increasing trends towards second opinions in oncology, [37] this support group aids patients in determining the most appropriate treatment by offering referrals with radiation oncologists certified by both the Japan Radiology Society and the Japanese Society for Radiation Oncology. Along with the referral service for second opinions, the Cancer Treatment Society for Citizens also offers educational programs and publishes articles by cancer specialists on its website to promote general awareness of contemporary cancer research and treatment options. Data collection Data collection occurred from January 9 to February 10, 2019, using the structured questionnaire. The printed survey questionnaire was distributed to all 524 Cancer Treatment Society members for Citizens registered on the society's mailing list with the society's quarterly newsletter on January 9, 2019. Members that agreed to participate in the study completed the questionnaire and returned it, as requested, via the enclosed self-addressed, stamped envelope by February 10, 2019. To mitigate the response biases, the authors were not directly involved in the survey distribution or collection.

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

163 164 Survey sheet 165 We compiled our cross-sectional questionnaire survey, taking into account previous 166 studies and the local context of Japanese cancer care.[38, 39] The survey included 51 167 questions covering the following items: 1) the status of disease progression and demographic characteristics such as gender, education level, and medical history; 2) 168 169 awareness of the physician-Pharma interactions, including physician receipt of gifts, 170 payments and research rewards from Pharma (e.g., "Do you know that some physicians 171 would receive pamphlets or leaflets concerning products manufactured by 172 pharmaceutical companies from their sales representatives?") on a three-point Likert 173 scale (Yes, No, or Not sure); 3) influence of the interactions' on trust (e.g., "How would 174 your trust in your physician be influenced if your physician received pamphlet or leaflet 175 with information about the products from a pharmaceutical sales representative?") on a 176 five-point Likert scale; 4) perception of trust and regulation on the interactions (e.g., 177 "Stricter regulations about gifts, meals, and honoraria from pharmaceutical companies to physicians are needed.") on a five-point Likert scale; 5) attitude towards the industrial 178

payments across professions (e.g., "It is problematic for physicians to receive gifts, meals, and other entertainment from pharmaceutical sales representatives.") on a five-point Likert scale; and 6) an open-ended question about participants' perception on the FCOI between Pharma and physicians ("Please freely describe your thoughts about non-research-related offerings from Pharma to a physician (e.g., gifts, free meals, monetary incentives for a lecture)"). The survey questions are described in greater detail in the Supplementary Methods (Supplementary Material 1). Data analysis The initial descriptive analysis included the patients' sociodemographic and clinical variables and all questions concerning participant awareness, influence on trust in 190 physicians, perceptions, and attitudes towards FCOI. Next, to assess the association between awareness (outcome variable 1) and the impact of physician-Pharma interaction on physicians' trustworthiness (outcome variable 2) and 194 each participant's sociodemographic and clinical factors, we constructed logistic

179

180

181

182

183

184

185

186

187

188

189

191

192

regression models for trust in physicians. We re-categorized the following variables as appropriate and set them as predictor variables: annual income, highest educational qualification, medical history, type of business, hospital types, cancer stage, year of diagnosis, experience with cancer recurrence, experience with pharmacotherapy, experience with radiotherapy, and experience with surgical treatments. Further in the logistic analysis, to assess the factors related to participant awareness and to ensure statistical stability, the awareness status was re-categorized into two groups with the outcome variable set as those who responded "Yes" to one or more of the 11 questions about awareness, and those who responded "No" or "Not sure" to all questions. Similarly, the relationship between influence on physicians' trust and the predictor variables was also assessed using logistic regression analysis. In the analysis of the influence on trust in physicians, the variables measuring physicians' trust were aggregated into two types, with the outcome variable set as those who reported "decreased trust in physicians" or "slightly decreased trust in physicians" on at least one question, and the other respondents. In both analyses, multicollinearity was of no concern (VIFs < 10).

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

These data analyses were informed by similar previous studies reported by Ammous et al. and Green et al. [38, 40] All analyses, including descriptive statistics, were performed using Stata version 15 (STATA Corp., College Station, TX, United States). Conversion of JPY to USD used the 2019 average monthly exchange rate of 109.0 JPY per USD. Lastly, participants' responses to the open-ended questions regarding perception on FCOI were analysed thematically, following Braun and Clarke.[41] 218 Ethics approval The Institutional Review Board of Medical Governance Research Institute granted ethics approval of this study (MG2018-07-0928), adhering to the Ministry of Health Labour and Welfare and The Ministry of Education guidelines, Culture, Sports, Science, and Technology in Japan. **Results** 226 **Participants**

211

212

213

214

215

216

217

219

220

221

222

223

224

All surveys returned by February 10, 2019, were considered. Of the 524 eligible survey participants, 96 completed the questionnaire (completion rate=18.3%). Table 1 presents participant sociodemographic and clinical characteristics. Respondents were predominantly male (67.7%, 63/93), older than 70 years (52.3%, 49/94), and 53.8% (50/93) had educational attainment of a bachelor's degree or higher. Further, 55.9% (52/93) were unemployed, and about half (46.5%, 40) had an annual household income of over \$36,697, roughly the average of Japanese households in 2018. Of the 89 respondents providing primary disease status, 69 (77.5%) were cancer patients, and 20 (22.5%) were non-cancer patients (e.g., family members of cancer patients).

Table 1. Demographic features of the study population.

Variables	
Gender, N (%)	
Male	63 (67.7)
Female	30 (32.3)
Missing	3
Age category, N (%)	
≦ 60	15 (16.0)
61-70	30 (31.9)
71-80	38 (40.4)
81-90	11 (11.7)
Missing	2
Annual family income, N (%)	
< 2 million JPY (< 18,349 USD)	6 (7.0)
2-4 million JPY (18,349-36,697 USD)	40 (46.5)
4-6 million JPY (36,697-55,046 USD)	14 (16.3)
6-8 million JPY (55,046-73,394 USD)	12 (14.0)
8-10 million JPY (73,394-91,743 USD)	5 (5.8)
>10 million JPY (>91,743 USD)	9 (10.5)
Missing	10
Type of business, N (%)	

I In annula va d	52 (55 0)
Unemployed	52 (55.9) 15 (16.1)
Self-employed	15 (16.1) 11 (11.8)
Full-time job	, ,
Part-time job Other	7 (7.5)
Missing	8 (8.6) 3
Educational background, N (%)	3
Less than high school graduate	1 (1.1)
High school graduate	27 (29.0)
Associate degree or diploma	15 (16.1)
Bachelor's degree or more	50 (53.8)
(bachelor, master and doctoral degree)	30 (33.0)
Missing	3
Type of cancer, N (%)	3
Not cancer patient	20 (22.5)
Prostate cancer	24 (27.0)
Lung cancer	5 (5.6)
Breast cancer	5 (5.6)
Colorectal cancer	4 (4.5)
Gastric cancer	4 (4.5)
Other type of cancer	27 (30.3)
Missing	7
Cancer's stage, N (%)*	
Stage 1	23 (35.9)
Stage 2	16 (25.0)
Stage 3	10 (15.6)
Stage 4	5 (7.7)
Unclear	10 (15.6)
Missing	5
Year of diagnosis, N (%)*	
2018	4 (5.8)
2017	6 (8.7)
2016	3 (4.4)
2015	4 (5.8)
Before 2015	52 (75.4)
Hospital, N (%)*	
Cancer hospital	20 (29.4)
National university	9 (13.2)
Private university	9 (13.2)
National municipal hospital	10 (14.7)
Private municipal hospital	11 (16.2)
Other hospital	9 (13.2)
Missing	1
Previous cancer recurrence*	
Yes	13 (20.0)
No	47 (72.3)
Not clear	5 (7.7)
Missing	4
Count of previous cancer reoccurrence, N (%)	440
1	6 (42.9)
2	2 (14.3)
3	1 (7.1)
6	1 (7.1)
7	1 (7.1)
10	1 (7.1)
Unknown	2 (14.3)
Treatment which you have ever had, N (%)***	

Anticancer drug	22 (16.5)
Molecularly targeted drug	5 (3.8)
Hormone therapy	23 (17.3)
Radiation therapy	37 (27.8)
Surgery	39 (29.3)
Other	4 (3.0)
Never	3 (2.3)
Treatment which you have now, N (%)*, **	
Anticancer drug	2 (2.9)
Molecularly targeted drug	2 (2.9)
Hormone therapy	10 (14.5)
Radiation therapy	2 (2.9)
Other	11 (15.9)
Not having	42 (60.9)

^{*} The denominator was the number of people with any type of cancer. (n=69)

242

243

244

245

246

247

248

249

250

251

252

Of the 69 participants self-identifying as cancer patients, 75.4% (52/64) received their diagnosis before 2015. Further, 30.9% (21/68) of these participants primarily received treatment at a municipal hospital, while 60.9% (42/69) did not actively receive any treatment during the survey period. Lastly, 39 (56.5%) reported previous pharmaceutical treatments for cancer, including anticancer drugs, molecularly targeted drugs, or hormone therapy.

Quantitative findings

Awareness of physician-Pharma interactions

Figure 1 presents the participants' awareness of physician-Pharma interactions. The

^{240 **} Multiple answers were possible.

Abbreviations: JPY; Japanese yen, USD; US dollar

proportion of the participants aware of these interactions ranged from 2.1% to 65.3%, depending on the type of interaction. The interaction with the largest proportion of participant awareness was pamphlets and leaflets (65.3%), followed by stationery (64.2%) and free drug samples (53.1%). In contrast, the participants were the least aware of possession of stocks (2.1%). Although Japanese companies belonging to the Japan Pharmaceutical Manufacturer Association have disclosed payments to healthcare sectors since 2013, only 10.5% (10/95) of the survey responders were aware of such disclosure. Overall, 80.2% (77/96) of participants were aware of at least one physician-Pharma interaction. Detailed results of awareness by participant demographic characteristics are shown in Supplementary Material 5. None of the sociodemographic and clinical variables in the logistic regression analysis significantly predicted awareness of physician-Pharma interactions ($p \ge 0.05$) (Supplementary Material 6). Figure 1. Participants' awareness of interactions between physicians and pharmaceutical companies.

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

269 Influence of physician-Pharma interactions on trust in physicians 270 Figure 2 shows the impact of physician-Pharma interactions on patients' trust in 271 physicians. Although participants overwhelmingly responded that most 272 physician-Pharma interactions neither increased nor decreased their trust in physicians, 273 81.2% (58.3% decrease in trust, 22.9% slightly decreased trust) agreed that stock 274 ownership would negatively impact their trust in physicians. Additionally, accepting 275 either honoraria for registering patients in industry-sponsored research (52.1% decrease 276 in trust, 26.0% slightly decreased trust) or lecture fees (31.6% decrease in trust, 30.5% 277 slightly decreased trust) also substantially impacted participant perceptions. Interestingly, 278 few participants reported that indirect gifts, such as accepting free samples of prescription 279 drugs (12.8% decrease in trust, 25.5% slightly decreased trust), would reduce trust in 280 physicians. On the other hand, participation in industry-sponsored research generally 281 appeared to increase physician trustfulness by 13.6% (increased trust 2.1%, slightly 282 increased trust 11.5%) among participants. Overall, 90.6% of participants marked 283 decreased trust or slightly decreased trust on at least one question. Associations between 284 participant demographic characteristics and trust in physicians are shown in

Supplementary Material 7. Our regression analysis revealed that none of the sociodemographic or clinical variables significantly predicted whether patients' trust in physicians would decrease or not $(p \ge 0.05)$ (Supplementary Material 8). Figure 2. Influence of physician-Pharma interactions on trust in physicians. Perception on physician-Pharma interactions Figure 3 details the reported perceptions on a series of statements regarding physician-Pharma interactions and regulations associated with each. Overall, a substantial proportion of participants either agreed or slightly agreed that gifts from pharmaceutical companies have a significant influence on physicians' prescription behavior (35.8% agree, 38.9% slightly agree). A similar proportion viewed such gifts as unethical (31.6% agree, 30.5% slightly agree), contributing to unnecessary prescriptions (34.7% agree, 37.9% slightly agree), and negatively influencing patients' trust in physicians (38.9% agree, 31.6% slightly agree). And while many participants acknowledged the need to regulate physician-Pharma interactions, more concluded that

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

there should be greater self-regulation by industry (60.0% agree, 26.3% slightly agree) or physicians (60.2% agree 24.7% slightly agree) as opposed to legal regulation (45.3% agree, 29.5% slightly agree). Figure 3. Participants' perceptions on statements regarding interactions between physicians and pharmaceutical companies and regulations associated with them. Figure 4 shows participants' perceptions on acceptable amounts and frequency of non-research payments from Pharma to physicians. In total, 75.9% of the participants considered an interaction worth 10,000 JPY (91.7 USD) or below as acceptable, and 92.8% believed that the annual amount should be less than 1 million JPY (9,174 USD). Further, 77.8% of the participants considered one interaction every few months as acceptable. Figure 4. Participants' perception of acceptable amounts and frequency of non-research payments from pharmaceutical companies to physicians.

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

Attitude towards various professional FCOI. Figure 5 shows the participants' perceptions towards potential FCOI in various professions, including court judges, referees, politicians, physicians, and business professionals. Overall, a larger percentage of participants considered it problematic for court judges, politicians, or referees to receive gifts and meals from lawyers (agree 92.6%, slightly agree 6.3%), lobbyists (agree 75.5%, slightly agree 20.2%), or players (agree 89.4%, slightly agree 4.3%), respectively, than for physicians to accept gifts from Pharma (agree 58.5%, if slightly agree 23.3%). Figure 5. Participant attitude about conflicts of interest among various professionals. **Qualitative findings** Open-ended responses A thematic analysis of the survey's open-ended question, responded to by 56 (58.3%) of

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

the participants, identified four themes: 1) Perception towards the FCOI, 2) Concerns about the participant's treatment, 3) Reasons for physician-Pharma interactions and 4) Possible solutions from the patient's perspective. Theme 1: Perception towards the FCOI The majority of respondents agreed that physicians should not receive honoraria except for research purposes. However, even the receipt of honoraria for research purposes was conditioned on the premise that such awards would not interfere with physicians' ability to deliver high-quality patient-centered care. "Never permit benefits except for research purposes. Pharmaceutical companies, including those who are involved in research, should realize that the pharmaceutical companies are responsible for the lives of people. We don't want doctors to accept one penny of honorarium." Further, concerning lecture fees, a few participants appeared to consider that physicians

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

deserve to receive payment to some extent due to the physicians' efforts in preparing for the lecture. "Physicians are busy and time-restricted, so I think it's reasonable for them to receive it (a lecture fee). But I disagree with any other kind of benefit-sharing between them, because that may hinder optimal selection of the prescription." The majority of respondents wanted the financial transactions to be minimized, except for reasonable research payments. This is in line with the results from our quantitative analysis. For example, more than half of the participants considered non-research benefits of less than 100,000 JPY (917 USD) per year to be appropriate. Theme 2: Concerns about the participant's treatment Many participants expressed concerns about the influence of physician-Pharma interactions on treatment decisions and the treatment they receive. Participants mostly wanted doctors to treat patients based on their authentic judgment and not be influenced

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

by these interactions. "Doctors are also human, and if they are incentivized, then they may have to make a judgment that is favored by a pharmaceutical company. I've heard of such things, and I think doctors should put their patients first, as cliché as it may sound. Patients trust their doctors and put their lives in doctor's hands. I hope that not all doctors are in favor of Pharma." "My former doctor used to go to 'study meetings' a lot. To treat my advanced cancer, this doctor strongly recommended a medicine that he had just learned about in these study meetings. Although I trusted him to treat me, having learned about the financial relationships between physicians and pharmaceutical industry in this research, now I would have made different decisions about his recommendations." In alignment with our quantitative analysis results, many participants expressed concern about the influence of physician-Pharma interactions on physician's prescription

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

decisions in general. Additionally, several participants voiced unease about their physicians and the treatments they received. Theme 3: Reasons of physician-Pharma interactions Many participants concluded that a lack of physician ethical norms could cause FCOI between Pharma and healthcare sectors. "I think it comes down to the ethics and morality of each physician." Besides physicians' morality, two participants raised the current government policy for science as an ongoing issue of physician-Pharma interactions. They indicated that the decline in the national budget for scientific research led to the financial dependence on Pharma. "I think there is also a problem with the way the Japanese government funds basic research, alongside physician ethics and morality, if we want to ensure that

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

(healthcare) is not controlled by pharmaceutical companies." In contrast to Themes 1 and 2, neither of these two potential reasons were clarified in the quantitative results. Theme 4: Possible solutions from the patient perspective The open-ended responses about possible solutions for FCOI comprised three main positions: improving public awareness of physician-Pharma interactions, strengthening legal or public FCOI regulation, and educating healthcare professionals on ethical norms. Several participants suggested possible solutions for the FCOI between Pharma and healthcare sectors. Improving public awareness of physician-Pharma interactions was the idea suggested most often. Also, regulating the FCOI by professional associations or law was suggested by several participants while also acknowledging the need for receipts for transport, meals, and

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

honoraria relating to lectures and research. These comments also supported the quantitative results that more than three-fourths of the participants agreed with some form of regulation. "If [doctors] give a lecture, [doctors] may get transportation, food, and honorarium. It is generally an acceptable amount of money. If the basis on which pharmaceutical companies decide the concrete amount of the payments to physicians is unclear, the criteria should be decided by the professional association or academic society, taking into account the age and experience of the speaker." On the other hand, a few participants insisted a regulatory regime for physician-Pharma interactions based on each physician's morality rather than on legal or public regulation. This would further indicate the need for the education of physicians on the perspective of ethical norms. **Discussion**

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

In this study, we investigated the awareness and perceptions of FCOI between Pharma and physicians among members of a Japanese cancer patient advocacy group demographically representative of the general Japanese cancer patient population.[42] We primarily found that most of the participants were aware of physician-Pharma interactions, although the extent of the awareness differed based on the nature of the interaction. We also found that participants mainly considered these interactions influential on clinical practice and agreed to the need for further regulation of physician-pharma interactions. Although the awareness of the interactions in this study, such as receipt of stationeries (64.2%), travel fees (35.8%), lecture fees (25.3%), and disclosure of payments from Pharma to the healthcare sector (10.5%), were within the scope of previous studies (55–76%, 17–33.7%, 20–46%, 7.3–18.8%, respectively),[12, 22, 24, 38, 43, 44] the awareness of receiving drug samples (53.1%) was significantly lower than studies in the US (87–93.9%).[43, 45] In contrast, the awareness of physicians conducting research for Pharma (47.4%), receipt of meals (50.5%), and receipt of textbooks (45.3%) were higher

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

than US and Lebanese studies (23–32%, 22–37%, 35–37%), respectively.[38, 40, 43] The underlying reasons for such differences among countries are not obvious. Still, stationaries and educational gifts, which could be present in clinicians' offices, were more likely to be recognized than personal payments for lectures, travel, or accommodations, a trend which we observed previously.[43, 45-47] One of the most interesting findings from this study was that despite ongoing disclosure efforts since 2013, only about 10% of participants knew major Japanese Pharma disclosed payments to physicians. Even so, the proportion of participants who were aware of such disclosures was within the range reported for previous studies conducted in the US (7.3%-18.8%).[12, 22, 24, 44] Nevertheless, this study's participants may have had a more robust general interest in awareness of FCOI between Pharma and healthcare sectors. The qualitative study's findings also revealed a lack of attentiveness on this issue, suggesting a need for proper countermeasure. Notably, during the study period on January 15, 2019, the Money Database was made publicly available in Japan. Since then, several academic papers and media reports have documented the financial relationships

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

among Pharma and various healthcare sectors. [20, 34-36, 48-50] This potentially contributed to a recent increase in public attention to the issue of FCOI in Japan and warrants a follow-up study to further evaluate this issue. This survey also demonstrated that most of the participants considered the presence of FCOI with Pharma as harming participants' trust in physicians. Interestingly, although the results of the qualitative analyses indicated that a majority of respondents believed FCOI relating to research were acceptable when framed in the context of physicians participating in Pharma sponsored research, our quantitative findings noted a larger proportion of the participants (25%) reporting a decrease of trust in physicians than those who reported an increase of trust (13.6%). Further, 78.1% of the participants indicated a loss of trust when physicians received Pharma payments for participating in a clinical trial. This finding starkly contrasts with previous studies in other countries where the receipt of payments for lectures or conducting Pharma sponsored research were viewed as a positive symbol of good physicians by the public. [23, 51, 52]. Given that clinical trials can have positive consequences, including improving management strategies of

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

specific conditions or expanding the treatment options of patients participating in clinical trials, this apparent skepticism of clinical trials among the Japanese public warrants attention. Nonetheless, FCOI between Pharma and physicians may cause bias in reporting research findings [53, 54] or medical scandals.[55] Thus, proper control of FCOI must accompany research involving Pharma. In this study, more than three-quarters of participants considered general FCOI with Pharma to be influential in physician prescription in a certain way. The observed value (75.9%) was the highest in several previous studies reported in other countries, ranging from 29% in Turkey to 75.6% in Canada.[38, 43-45, 56, 57] Also, more participants agreed that physician-Pharma interactions would increase healthcare costs (72.6%) more so than other studies (33%–67.3%).[43] A possible reason for this may relate to the study population comprising cancer patients or their advocates. Essentially, this population is characterized by more significant health risks with few treatment alternatives outside of seeing a physician, [58-60] and associated regular and long-term care [61, 62], leading to greater familiarity and trust in their physicians.[58]

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

Aspects of Japanese culture likely also contribute to our findings. In particular, the Japanese medical profession has traditionally been held sacred, with physicians considered above reproach due to their ethos. Often more so than in other countries. Moreover, there exists a deep sense of shame and extreme disdain associated with improper behavior. [63, 64] Consequently, physicians with inappropriate financial entanglements may be seen as a kind of "defilement," leading to distrust or disgust of such physicians by Japanese patients more strongly than among those in other countries. More than 80% of participants answered that gifts accepted by physicians from Pharma were problematic. However, compared to other fields, fewer people considered accepting gifts in the medical field as more problematic than the legal, athletic, and political fields and less problematic compared to the general business world. This trend was similar to that observed in the US.[40] However, our study showed that more participants considered the physician-Pharma interactions to be unethical than their counterparts in the US (58.5% unethical and 22.3% somewhat unethical in our study versus 44%

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

unethical and 15% somewhat unethical in the US).[40] Although we were unable to find an international comparison of physicians' public perception related to ethical norms, our findings indicated that a greater percentage of the Japanese public might expect physicians to be ethical than the general public in other countries. **Clinical implementation** In completing the questionnaires, participants provided several key perspectives in their quantitative and open-ended qualitative responses to properly improve patient-centered care and manage FCOI between Pharma and healthcare sectors. As our previous studies revealed, the current framework for regulating FCOI between Pharma and healthcare sectors in Japan still has room for improvement, particularly regarding transparency. [20, 21, 35, 36, 65] Regarding FCOI, we observed among cancer patients a consensus that physicians, professional associations, and Pharma should exhibit higher ethical standards and self-regulate their FCOI rather than rely on government regulation. This perspective has important repercussions for future

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

discussions on improving the transparency of FCOI in the Japanese healthcare system. One likely countermeasure would be developing voluntary disclosure databases initiated by professional organizations akin to Disclosure UK or Disclosure Australia.[9, 66] Another option would include the rigorous and legally binding FCOI disclosure standards established by the Sunshine Act and the Open Payment database in the US or the Transparency in Healthcare database in France. [5, 10-12] Second, our survey elucidated that nearly 20% of participants were unaware of many kinds of physician-Pharma interactions despite representing a population with a high level of interest in medical issues. Given that numerous studies showed that FCOI between Pharma and healthcare sectors influence patient treatment [6, 67, 68] and that many patients wanted to know about these conflicts [12, 52, 69-71], it is noteworthy that patients could benefit significantly from knowledge about FCOI before choosing doctors and treatments. [44, 52, 72] Therefore, we suggest the possibility of exploring seminars focusing on direct communications with the general public to build stronger relationships between Pharma, healthcare sectors, and patients and to gain patient trust.[73] One study

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

from Australia showed that small-sized workshops help improve patient knowledge about FCOI.[74] In the meantime, the potential for increasing patient awareness of FCOI between Pharma and healthcare sectors may disrupt the long-standing, trusting relationship between patients and their physicians. As Kanter previously hypothesized, [72] our results suggest that patients with long-term and severe diseases like cancer would lose faith in their physicians over FCOI. Moreover, these concerns extended to a physician's judgment of treatment options wherein some participants expressed similar concerns about the treatment they received. Specifically, this raises concerns about the general awareness of FCOI between Pharma and healthcare sectors, which could lead to some patients declining effective treatments suggested by their physicians. Therefore, careful consideration should be paid in communicating with patients about FCOI between Pharma and healthcare sectors. Third, some participants suggested that there was a need to educate physicians about

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

FCOI. According to Medical Professionalism in the New Millennium: A Physician Charter, maintaining trust by managing FCOI is one of the fundamental responsibilities for all physicians.[75] However, only one-third of Japanese medical schools undergo formal training on FCOI between Pharma and healthcare sectors.[76] Most physician-Pharma interactions are rooted in the first year of a physician's training, after which physicians are continuously exposed to such interactions. [77, 78] For this reason, few physicians question these interactions or their influence on their clinical practice, and some physicians are not honest with their patients about FCOI.[76, 79-82] For example, more than 98% of Japanese medical students have financial interactions with Pharma.[83] Also, several studies revealed that junior physicians, more so than senior physicians, were more likely to accept interactions with Pharma[84, 85] and consider them appropriate and valuable.[85] Therefore, we would suggest that all medical schools establish a curriculum on FCOI addressing these relationships' undue influence on clinical practice [6, 68, 86] and their impact on patient trust and care. [72] Given that even preclinical medical students can interact with Pharma, it might be advisable for this curriculum to be implemented early, by the second or third year in Japan. [76, 87, 88]

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

Limitations

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

Our study has several limitations. First, it is worth noting that the response rate was relatively low at 18.3%. Many questions and the sensitive nature of the topic may have caused candidates to evade answering questions. The base response rate suggests that only candidates with a relatively strong interest in or problematic awareness of FCOI between Pharma and healthcare professionals may have participated in this study. Second, our study was conducted among the members of a cancer patient advocacy organization, many of whom have much more contact with Pharma and healthcare professionals than the general public and presumably greater interest in medical issues. Further, compared to Japan's general cancer population in 2015, the current study population tended to be more male but with a similar age distribution.[42] Therefore, this study should be interpreted with caution about whether the results reflect the general Japanese public's attitudes. Nevertheless, this study's findings mirror existing perceptions among cancer patients towards the FCOI of physicians. Third, we did not collect data on the physicians who oversaw the participants' treatments as cancer patients. Other unexamined confounding

factors, such as physician specialty, details of their FCOI with Pharma, would influence the differences of participant awareness and perception of physician-Pharma interactions.[12, 24, 57] Despite the limitations, to the best of our knowledge, this is the first study to examine the awareness and perceptions of physician-Pharma interactions among non-healthcare professionals in Japan. The opinions of cancer patients and the supporting public could help explore appropriate FCOI management methods in Japan and other countries. Conclusion While most participants were aware of some FCOI between healthcare sectors and Pharma in Japan, its extent differed much depending on the interactions. Participants also reported a significantly decreased trust in physicians who received personal gifts and payments than those accepting office-use related gifts. In addition, several participants expected that physicians should be highly ethical, minimize FCOI outside of research, and assume that FCOI disproportionately influences a physicians' clinical practice, increases healthcare costs, and lowers patients' trust in physicians. Further steps are

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

- required to improve patient awareness of FCOI, patient trust, and transparency in
- healthcare. These include improving public awareness with seminars focusing on direct
- 607 physician-patient communication, more patient-oriented regulation of FCOI, and
- educating medical students and physicians about FCOI.

References

- 612 1. Institute of Medicine Committee on Quality of Health Care in A.
- 613 Crossing the Quality Chasm: A New Health System for the 21st Century.
- 614 Washington (DC): National Academies Press (US)
- 615 Copyright 2001 by the National Academy of Sciences. All rights reserved.;
- 616 2001.

609

610

- 617 2. Ozaki A, Saito H, Senoo Y, Sawano T, Shimada Y, Kobashi Y, et al.
- 618 Overview and transparency of non-research payments to healthcare
- 619 organizations and healthcare professionals from pharmaceutical companies
- 620 in Japan: Analysis of payment data in 2016. Health Policy.
- 621 2020;124(7):727-35. Epub 2020/05/23. doi:
- 622 10.1016/j. healthpol. 2020.03.011. PubMed PMID: 32439213.
- 623 3. Fickweiler F, Fickweiler W, Urbach E. Interactions between
- 624 physicians and the pharmaceutical industry generally and sales
- 625 representatives specifically and their association with physicians'
- 626 attitudes and prescribing habits: a systematic review. BMJ Open.
- 627 2017;7(9):e016408. Epub 2017/10/01. doi: 10.1136/bmjopen-2017-016408.
- 628 PubMed PMID: 28963287; PubMed Central PMCID: PMCPMC5623540.
- 629 4. Ozieranski P, Csanadi M, Rickard E, Tchilingirian J, Mulinari S.

- 630 Analysis of Pharmaceutical Industry Payments to UK Health Care
- 631 Organizations in 2015. JAMA Netw Open. 2019;2(6):e196253. Epub 2019/06/22.
- 632 doi: 10.1001/jamanetworkopen.2019.6253. PubMed PMID: 31225896; PubMed
- 633 Central PMCID: PMCPMC6593961.
- 634 5. Goupil B, Balusson F, Naudet F, Esvan M, Bastian B, Chapron A, et
- al. Association between gifts from pharmaceutical companies to French
- 636 general practitioners and their drug prescribing patterns in 2016:
- 637 retrospective study using the French Transparency in Healthcare and
- 638 National Health Data System databases. BMJ. 2019;367:16015. Epub
- 639 2019/11/07. doi: 10.1136/bmj.16015. PubMed PMID: 31690553; PubMed Central
- PMCID: PMCPMC6830500 at www.icmje.org/coi_disclosure.pdf and declare: no
- 641 financial relationships with any organisations that might have an interest
- in the submitted work in the previous three years; AC reports personal fees
- and non-financial support from Roche, personal fees and non-financial
- 644 support from Novartis Pharma, and personal fees from Congres colloques
- conventions, outside the submitted work; no other relationships or
- 646 activities that could appear to have influenced the submitted work.
- 647 6. Brax H, Fadlallah R, Al-Khaled L, Kahale LA, Nas H, El-Jardali F,
- 648 et al. Association between physicians' interaction with pharmaceutical
- 649 companies and their clinical practices: A systematic review and
- 650 meta-analysis. PLoS One. 2017;12(4):e0175493. Epub 2017/04/14. doi:
- 651 10.1371/journal.pone.0175493. PubMed PMID: 28406971; PubMed Central
- 652 PMCID: PMCPMC5391068.
- 653 7. Catalyst N. What Is Patient-Centered Care? NEJM Catalyst.
- 654 2017;3(1).
- 655 8. Institute of Medicine. Conflict of Interest in Medical Research,
- 656 Education, and Practice. Lo B, Field MJ, editors. Washington, DC: The
- 657 National Academies Press; 2009. 436 p.
- 658 9. Moynihan R, Bero L, Hill S, Johansson M, Lexchin J, Macdonald H,
- 659 et al. Pathways to independence: towards producing and using trustworthy
- 660 evidence. BMJ. 2019;367:16576. Epub 2019/12/05. doi: 10.1136/bmj.16576.
- 661 PubMed PMID: 31796508.

- 662 10. Kanter GP, Loewenstein G. Evaluating Open Payments. JAMA.
- 663 2019;322(5):401-2. doi: 10.1001/jama.2019.8171.
- 664 11. Santhakumar S, Adashi EY. The Physician Payment Sunshine Act:
- 665 Testing the Value of Transparency. JAMA. 2015;313(1):23-4. doi:
- 666 10.1001/jama.2014.15472.
- 667 12. Stein GE, Kamler JJ, Chang JS. Ophthalmology Patient Perceptions
- of Open Payments Information. JAMA Ophthalmology. 2018;136(12):1375-81.
- 669 doi: 10.1001/jamaophthalmol.2018.4167.
- 670 13. Stoll M, Hubenschmid L, Koch C, Lieb K. Voluntary disclosures of
- 671 payments from pharmaceutical companies to healthcare professionals in
- 672 Germany: a descriptive study of disclosures in 2015 and 2016. BMJ Open.
- 673 2020;10(9):e037395. doi: 10.1136/bmjopen-2020-037395.
- 674 14. Napierala H, Schäfer L, Schott G, Schurig N, Lempert T. Management
- of financial conflicts of interests in clinical practice guidelines in
- 676 Germany: results from the public database GuidelineWatch. BMC Medical
- 677 Ethics. 2018;19(1):65. doi: 10.1186/s12910-018-0309-y.
- 678 15. Mulinari S, Ozieranski P. Disclosure of payments by pharmaceutical
- 679 companies to healthcare professionals in the UK: analysis of the
- 680 Association of the British Pharmaceutical Industry's Disclosure UK
- 681 database, 2015 and 2016 cohorts. BMJ Open. 2018;8(10):e023094. doi:
- 682 10.1136/bmjopen-2018-023094.
- 683 16. Adlington K, Godlee F. Disclosure UK: transparency should no longer
- 684 be an optional extra. BMJ. 2016;354:i3730. doi: 10.1136/bmj.i3730.
- 685 17. Ozieranski P, Rickard E, Mulinari S. Exposing drug industry funding
- 686 of UK patient organisations. BMJ. 2019;365:11806. Epub 2019/05/28. doi:
- 687 10.1136/bmj.11806. PubMed PMID: 31122928; PubMed Central PMCID:
- 688 PMCPMC6529850 interests and declare the following: SM and PO's work on the
- 689 study reported in this paper was supported by the grant "What can be learnt
- 690 from the new pharmaceutical industry payment disclosures?" awarded by the
- 691 Swedish Research Council for Health, Working Life and Welfare (FORTE
- 692 #2016-00875). ER's work was funded through the above grant. The funding
- 693 body has played no part in the design or conduct of this analysis. We have

- 694 no other competing interests to declare.
- 695 18. Transparency Reporting [Internet]. Medicines Australia. 2019
- 696 [cited October 28, 2020]. Available from:
- 697 https://www.disclosureaustralia.com.au/search/.
- 698 19. Pokorny AMJ, Bero LA, Moynihan R, Mintzes BJ. Industry payments
- 699 to Australian medical oncologists and clinical haematologists: a
- 700 cross-sectional analysis of publicly-available disclosures. Intern Med J.
- 701 2020; n/a (n/a). Epub 2020/08/04. doi: 10.1111/imj.15005. PubMed PMID:
- 702 32744396.
- 703 20. Sawano T, Ozaki A, Saito H, Shimada Y, Tanimoto T. Pharmaceutical
- 704 Company Payments to Japanese Government Drug Regulation Committee Members.
- 705 Clin Pharmacol Ther. 2020;108(5):1049-54. Epub 2020/05/19. doi:
- 706 10.1002/cpt.1892. PubMed PMID: 32420619.
- 707 21. Murayama A, Ozaki A, Saito H, Sawano T, Shimada Y, Yamamoto K, et
- 708 al. Pharmaceutical company payments to dermatology Clinical Practice
- 709 Guideline authors in Japan. PLoS One. 2020;15(10):e0239610. Epub
- 710 2020/10/14. doi: 10.1371/journal.pone.0239610. PubMed PMID: 33048952;
- 711 PubMed Central PMCID: PMCPMC7553305 Pharmaciez. Also Dr. Saito received
- 712 personal fees from TAIHO Pharmaceutical Co., Ltd. outside the scope of the
- 713 submitted work. Drs. Ozaki and Tanimoto received personal fees from Medical
- 714 Network Systems outside the scope of the submitted work. This donation from
- 715 Ain Pharmaceiz does not alter our adherence to PLoS ONE policies on sharing
- 716 data and materials.
- 717 22. Kanter GP, Carpenter D, Lehmann L, Mello MM. Effect of the public
- 718 disclosure of industry payments information on patients: results from a
- 719 population-based natural experiment. BMJ Open. 2019;9(2):e024020. Epub
- 720 2019/03/04. doi: 10.1136/bmjopen-2018-024020. PubMed PMID: 30826793;
- 721 PubMed Central PMCID: PMCPMC6398799.
- 722 23. Hampson LA, Agrawal M, Joffe S, Gross CP, Verter J, Emanuel EJ.
- 723 Patients' views on financial conflicts of interest in cancer research
- 724 trials. N Engl J Med. 2006;355(22):2330-7. Epub 2006/12/01. doi:
- 725 10.1056/NEJMsa064160. PubMed PMID: 17135586.

- 726 24. Pham-Kanter G, Mello MM, Lehmann LS, Campbell EG, Carpenter D.
- 727 Public Awareness of and Contact With Physicians Who Receive Industry
- 728 Payments: A National Survey. Journal of General Internal Medicine.
- 729 2017; 32 (7):767-74. doi: 10.1007/s11606-017-4012-3.
- 730 25. Kanter GP, Carpenter D, Lehmann LS, Mello MM. US Nationwide
- 731 Disclosure of Industry Payments and Public Trust in Physicians. JAMA
- 732 Network Open. 2019;2(4):e191947-e. doi:
- 733 10.1001/jamanetworkopen. 2019.1947.
- 734 26. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer
- 735 Journal for Clinicians. 2019;69(1):7-34. doi: 10.3322/caac.21551.
- 736 27. Ayyar BV, Arora S, O' Kennedy R. Coming-of-Age of Antibodies in
- 737 Cancer Therapeutics. Trends in Pharmacological Sciences.
- 738 2016;37(12):1009-28. doi: https://doi.org/10.1016/j.tips.2016.09.005.
- 739 28. Lagassé HAD, Alexaki A, Simhadri VL, Katagiri NH, Jankowski W,
- 740 Sauna ZE, et al. Recent advances in (therapeutic protein) drug development.
- 741 F1000Res. 2017;6:113-. doi: 10.12688/f1000research.9970.1. PubMed PMID:
- 742 28232867.
- 743 29. Tay-Teo K, Ilbawi A, Hill SR. Comparison of Sales Income and
- Research and Development Costs for FDA-Approved Cancer Drugs Sold by
- 745 Originator Drug Companies. JAMA Network Open. 2019;2(1):e186875-e. doi:
- 746 10.1001/jamanetworkopen. 2018.6875.
- 747 30. Aitken M, Kleinrock M, Simorellis A, Nass D. The global use of
- 748 medicine in 2019 and outlook to 2023. USA: IQVIA. 2019.
- 749 31. Fuji Keizai Management Co. Ltd. Ethical pharmaceutical data book
- 750 2018-2019. 2019 June 5. Report No.
- 751 32. Japan Pharmaceutical Manufacturers Association. Transparency
- 752 guideline for the relation between corporate activities and medical
- 753 institutions [in Japanese] 2018 [cited 2019 December 14]. Available from:
- 754 http://www.jpma.or.jp/english/policies_guidelines/transparency_guideli
- 755 ne. html.
- 756 33. "Money for Docs" database [Internet]. Waseda Chronicle
- 757 the Medical Governance Research Institute. 2020. Available from:

- 758 https://db.wasedachronicle.org/.
- 759 34. Saito H, Ozaki A, Kobayashi Y, Sawano T, Tanimoto T. Pharmaceutical
- 760 Company Payments to Executive Board Members of Professional Medical
- 761 Associations in Japan. JAMA Intern Med. 2019;179 (4):578-80. Epub
- 762 2019/02/05. doi: 10.1001/jamainternmed.2018.7283. PubMed PMID: 30715087;
- 763 PubMed Central PMCID: PMCPMC6450293.
- 764 35. Ozaki A, Saito H, Onoue Y, Sawano T, Shimada Y, Somekawa Y, et al.
- 765 Pharmaceutical payments to certified oncology specialists in Japan in 2016:
- 766 a retrospective observational cross-sectional analysis. BMJ Open.
- 767 2019;9(9):e028805. Epub 2019/09/09. doi: 10.1136/bmjopen-2018-028805.
- 768 PubMed PMID: 31494604; PubMed Central PMCID: PMCPMC6731803.
- 769 36. Saito H, Ozaki A, Sawano T, Shimada Y, Tanimoto T. Evaluation of
- 770 Pharmaceutical Company Payments and Conflict of Interest Disclosures Among
- 771 Oncology Clinical Practice Guideline Authors in Japan. JAMA Netw Open.
- 772 2019;2(4):e192834. Epub 2019/04/27. doi:
- 773 10.1001/jamanetworkopen. 2019. 2834. PubMed PMID: 31026027; PubMed Central
- 774 PMCID: PMCPMC6487566.
- 775 37. Hillen MA, Medendorp NM, Daams JG, Smets EMA. Patient-Driven Second
- 776 Opinions in Oncology: A Systematic Review. Oncologist.
- 777 2017;22 (10):1197-211. Epub 2017/06/12. doi:
- 778 10.1634/theoncologist.2016-0429. PubMed PMID: 28606972.
- 779 38. Ammous A, Bou Zein Eddine S, Dani A, Dbaibou J, El-Asmar JM, Sadder
- 780 L, et al. Awareness and attitudes of the Lebanese population with regard
- 781 to physician-pharmaceutical company interaction: a survey study. BMJ Open.
- 782 2017;7(3):e013041. Epub 2017/04/02. doi: 10.1136/bmjopen-2016-013041.
- 783 PubMed PMID: 28363922; PubMed Central PMCID: PMCPMC5387964.
- 784 39. National Cancer Center Center for Cancer Control and Information
- 785 Services. Summary report of hospital-based cancer registry in 2018. Online:
- 786 2019 December. Report No.
- 787 40. Green MJ, Masters R, James B, Simmons B, Lehman E. Do gifts from
- 788 the pharmaceutical industry affect trust in physicians? Fam Med.
- 789 2012;44(5):325-31. Epub 2012/10/03. PubMed PMID: 23027114.

- 790 41. Braun V, Clarke V. Using thematic analysis in psychology.
- 791 Qualitative Research in Psychology. 2006;3(2):77-101. doi:
- 792 10. 1191/1478088706qp063oa.
- 793 42. Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H,
- 794 et al. Cancer incidence and incidence rates in Japan in 2009: a study of
- 795 32 population-based cancer registries for the Monitoring of Cancer
- 796 Incidence in Japan (MCIJ) project. Japanese Journal of Clinical Oncology.
- 797 2015;45(9):884-91. doi: 10.1093/jjco/hyv088.
- 798 43. Fadlallah R, Nas H, Naamani D, El-Jardali F, Hammoura I, Al-Khaled
- 799 L, et al. Knowledge, Beliefs and Attitudes of Patients and the General
- 800 Public towards the Interactions of Physicians with the Pharmaceutical and
- the Device Industry: A Systematic Review. PLOS ONE. 2016;11(8):e0160540.
- 802 doi: 10.1371/journal.pone.0160540.
- 803 44. Lopez J, Naved BA, Pradeep T, Pineault K, Purvis T, Macmillan A,
- 804 et al. What Do Plastic Surgery Patients Think of Financial Conflicts of
- 805 Interest and the Sunshine Act? Annals of Plastic Surgery.
- 806 2019;82(6):597-603. doi: 10.1097/sap.000000000001756. PubMed PMID:
- 807 00000637-201906000-00003.
- 808 45. Jastifer J, Roberts S. Patients' Awareness of and Attitudes toward
- 809 Gifts from Pharmaceutical Companies to Physicians. International Journal
- 810 of Health Services. 2009;39(2):405-14. doi: 10.2190/HS.39.2.j.
- 811 46. Blake RL, Jr., Early EK. Patients' attitudes about gifts to
- 812 physicians from pharmaceutical companies. J Am Board Fam Pract.
- 813 1995;8(6):457-64. Epub 1995/11/01. PubMed PMID: 8585404.
- 814 47. Mainous AG, 3rd, Hueston WJ, Rich EC. Patient perceptions of
- 815 physician acceptance of gifts from the pharmaceutical industry. Arch Fam
- 816 Med. 1995;4(4):335-9. Epub 1995/04/01. doi: 10.1001/archfami.4.4.335.
- 817 PubMed PMID: 7711920.
- 818 48. Saito H, Ozaki A, Sawano T, Shimada Y, Yamamoto K, Suzuki Y, et
- 819 al. Pharmaceutical Company Payments to the Professors of Orthopaedic
- 820 Surgery Departments in Japan. JBJS. 2020;102(9):e39. doi:
- 821 10.2106/jbjs.19.01005. PubMed PMID: 00004623-202005060-00017.

- 822 49. Saito H, Tani Y, Ozaki A, Sawano T, Shimada Y, Yamamoto K, et al.
- 823 Financial ties between authors of the clinical practice guidelines and
- 824 pharmaceutical companies: an example from Japan. Clin Microbiol Infect.
- 825 2019;25 (11):1304-6. Epub 2019/08/12. doi: 10.1016/j.cmi.2019.07.025.
- 826 PubMed PMID: 31401175.
- 827 50. Harada K, Ozaki A, Saito H, Sawano T, Yamamoto K, Murayama A, et
- 828 al. Financial payments made by pharmaceutical companies to the authors of
- 329 Japanese hematology clinical practice guidelines between 2016 and 2017.
- 830 Health Policy. 2021;125(3):320-6. Epub 2021/01/03. doi:
- 831 10.1016/j. healthpol. 2020.12.005. PubMed PMID: 33386174.
- 832 51. Fisher CG, DiPaola CP, Noonan VK, Bailey C, Dvorak MFS.
- 833 Physician-industry conflict of interest: public opinion regarding
- 834 industry-sponsored research. Journal of Neurosurgery: Spine SPI.
- 835 2012;17(1):1. doi: 10.3171/2012.4. Spine11869.
- 836 52. DiPaola CP, Dea N, Noonan VK, Bailey CS, Dvorak MFS, Fisher CG.
- 837 Surgeon-industry conflict of interest: survey of North Americans' opinions
- 838 regarding surgeons consulting with industry. The Spine Journal.
- 839 2014;14(4):584-91. doi: https://doi.org/10.1016/j.spinee.2013.06.028.
- 840 53. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence
- 841 b(i) ased medicine—selective reporting from studies sponsored by
- 842 pharmaceutical industry: review of studies in new drug applications. BMJ.
- 843 2003;326 (7400):1171-3. Epub 2003/05/31. doi: 10.1136/bmj.326.7400.1171.
- PubMed PMID: 12775615; PubMed Central PMCID: PMCPMC156459.
- 845 54. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry
- 846 sponsorship and research outcome and quality: systematic review. BMJ.
- 847 2003;326 (7400):1167-70. Epub 2003/05/31. doi: 10.1136/bmj.326.7400.1167.
- PubMed PMID: 12775614; PubMed Central PMCID: PMCPMC156458.
- 849 55. Mullard A. Mediator scandal rocks French medical community. The
- 850 Lancet. 2011;377 (9769):890-2. doi: 10.1016/S0140-6736 (11)60334-6.
- 851 56. Holbrook A, Lexchin J, Pullenayegum E, Campbell C, Marlow B, Troyan
- 852 S, et al. What do Canadians think about physician-pharmaceutical industry
- 853 interactions? Health Policy. 2013;112(3):255-63. Epub 2013/05/29. doi:

- 854 10.1016/j. healthpol. 2013.04.020. PubMed PMID: 23711633.
- 855 57. Niforatos JD, Chaitoff A, Mercer MB, Yu P-C, Rose SL. Association
- 856 Between Public Trust and Provider Specialty Among Physicians With Financial
- 857 Conflicts of Interest. Mayo Clinic Proceedings. 2019;94(12):2467-75. doi:
- 858 https://doi.org/10.1016/j.mayocp.2019.07.009.
- 859 58. Gidman W, Ward P, McGregor L. Understanding public trust in
- 860 services provided by community pharmacists relative to those provided by
- 861 general practitioners: a qualitative study. BMJ Open. 2012;2(3):e000939.
- 862 doi: 10.1136/bmjopen-2012-000939.
- 863 59. Ward P, Coates A. 'We shed tears, but there is no one there to
- 864 wipe them up for us': narratives of (mis) trust in a materially deprived
- 865 community. Health. 2006;10(3):283-301. doi: 10.1177/1363459306064481.
- 866 PubMed PMID: 16775016.
- 867 60. Hall MA, Dugan E, Zheng B, Mishra AK. Trust in Physicians and
- 868 Medical Institutions: What Is It, Can It Be Measured, and Does It Matter?
- 869 The Milbank Quarterly. 2001;79 (4):613-39. doi:
- 870 https://doi.org/10.1111/1468-0009.00223.
- 871 61. Luhmann N, Gambetta D. Trust: making and breaking cooperative
- 872 relations. Familiarity, confidence, trust: problems and alternatives New
- 873 York: Basil Blackwell. 1988:94-107.
- 874 62. Luhmann N. Trust: A mechanism for the reduction of social
- 875 complexity. Trust and power: Two works by Niklas Luhmann. 1979:1-103.
- 876 63. Benedict R. The chrysanthemum and the sword; patterns of Japanese
- 877 culture. 1946.
- 878 64. Yanagida K. A Vulgar Man's View of Life (<Feature> What Ruth
- 879 Benedict's The Chrysanthemum and the Sword offers). The Japanese journal
- 880 of ethnology. 1950;14(4):p. 290-7. doi:
- 881 https://doi.org/10.14890/minkennewseries.14.4_290.
- 882 65. Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T.
- 883 Financial conflicts of interest between pharmaceutical companies and the
- 884 authors of urology clinical practice guidelines in Japan. Int Urogynecol
- 885 J. 2021;32(2):443-51. Epub 2020/11/06. doi: 10.1007/s00192-020-04547-3.

- 886 PubMed PMID: 33151353.
- 887 66. Fudman D, Feuerstein JD. The Call for Greater Transparency in
- 888 Conflicts of Interest. JAMA Netw Open. 2018;1(8):e186342. Epub 2019/01/16.
- 889 doi: 10.1001/jamanetworkopen.2018.6342. PubMed PMID: 30646322.
- 890 67. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J,
- 891 Othman N, et al. Information from pharmaceutical companies and the quality,
- 892 quantity, and cost of physicians' prescribing: a systematic review. PLoS
- 893 Med. 2010;7(10):e1000352. Epub 2010/10/27. doi:
- 894 10.1371/journal.pmed.1000352. PubMed PMID: 20976098; PubMed Central
- 895 PMCID: PMCPMC2957394 BM, JL, NO, and AV are members of Healthy Skepticism
- 896 Inc. Healthy Skepticism is an international nonprofit research, education,
- and advocacy association with the main aim of reducing harm from misleading
- 898 health information. PRM is the director of Healthy Skepticism Inc., and
- 899 is mostly unpaid. PRM's wife and two of his daughters are part-time
- 900 employees of Healthy Skepticism Inc. JL is a member of the management
- 901 committee of Healthy Skepticism.
- 902 68. Mitchell AP, Trivedi NU, Gennarelli RL, Chimonas S, Tabatabai SM,
- 903 Goldberg J, et al. Are Financial Payments From the Pharmaceutical Industry
- 904 Associated With Physician Prescribing?: A Systematic Review. Ann Intern
- 905 Med. 2020. Epub 2020/11/24. doi: 10.7326/m20-5665. PubMed PMID: 33226858.
- 906 69. Wen L. Patients can't trust doctors' advice if we hide our
- 907 financial connections with drug companies. BMJ: British Medical Journal.
- 908 2014;348:g167. doi: 10.1136/bmj.g167.
- 909 70. Tattersall MH, Dimoska A, Gan K. Patients expect transparency in
- 910 doctors' relationships with the pharmaceutical industry. Med J Aust.
- 911 2009;190(2):65-8. Epub 2009/02/25. PubMed PMID: 19236290.
- 912 71. Edwards D, Ballantyne A. Patient awareness and concern regarding
- 913 pharmaceutical manufacturer interactions with doctors. Intern Med J.
- 914 2009; 39 (3):191-6. Epub 2009/04/23. doi: 10.1111/j.1445-5994.2008.01887. x.
- 915 PubMed PMID: 19383067.
- 916 72. Pham-Kanter G. Act II of the Sunshine Act. PLoS Med.
- 917 2014;11 (11):e1001754. Epub 2014/11/05. doi: 10.1371/journal.pmed.1001754.

- 918 PubMed PMID: 25369363; PubMed Central PMCID: PMCPMC4219660.
- 919 73. Ozaki A, Murayama A, Saito H, Sawano T, Harada K, Senoo Y, et al.
- 920 Transparency Is Not Enough: How Can We Improve the Management of Financial
- 921 Conflicts of Interest Between Pharma and Healthcare Sectors? Clin Pharmacol
- 922 Ther. 2020. Epub 2020/12/31. doi: 10.1002/cpt.2126. PubMed PMID: 33377498.
- 923 74. Moynihan R, Fabbri A, Parker L, Bero L. Mixed methods evaluation
- 924 of workshops for citizen health advocates about financial conflicts of
- 925 interests in healthcare. BMJ Open. 2020;10(5):e034195. doi:
- 926 10.1136/bmjopen-2019-034195.
- 927 75. Medicine AFABoI, Medicine A-AFACoP-ASoI, European Federation of
- 928 Internal M. Medical professionalism in the new millennium: a physician
- 929 charter. Ann Intern Med. 2002;136(3):243-6. Epub 2002/02/06. doi:
- 930 10.7326/0003-4819-136-3-200202050-00012. PubMed PMID: 11827500.
- 931 76. Saito S, Maeno T, Miyata Y, Maeno T. Medical students' attitudes
- 932 toward interactions with the pharmaceutical industry: a national survey
- 933 in Japan. BMC Medical Education. 2018;18(1):286. doi:
- 934 10.1186/s12909-018-1394-9.
- 935 77. Evans DV, Desnick L, Keys T. Pharma Exposure Occurs Early in
- 936 Training and More Often in Rural Clinical Sites. Academic Medicine.
- 937 2016;91(1).
- 938 78. Fitz MM, Homan D, Reddy S, Griffith CHI, Baker E, Simpson KP. The
- 939 Hidden Curriculum: Medical Students' Changing Opinions toward the
- 940 Pharmaceutical Industry. Academic Medicine. 2007;82(10):S1-S3. doi:
- 941 10.1097/ACM.0b013e31813e7f02. PubMed PMID: 00001888-200710001-00001.
- 942 79. Saito S, Mukohara K, Bito S. Japanese Practicing Physicians'
- 943 Relationships with Pharmaceutical Representatives: A National Survey. PLOS
- 944 ONE. 2010; 5(8):e12193. doi: 10.1371/journal.pone.0012193.
- 945 80. Cain DM, Detsky AS. Everyone's a Little Bit Biased (Even
- 946 Physicians). JAMA. 2008;299(24):2893-5. doi: 10.1001/jama.299.24.2893.
- 947 81. Lea D, Spigset O, Slørdal L. Norwegian medical students' attitudes
- 948 towards the pharmaceutical industry. Eur J Clin Pharmacol.
- 949 2010;66 (7):727-33. Epub 2010/03/20. doi: 10.1007/s00228-010-0805-6.

- 950 PubMed PMID: 20300742.
- 951 82. Iezzoni LI, Rao SR, DesRoches CM, Vogeli C, Campbell EG. Survey
- 952 shows that at least some physicians are not always open or honest with
- 953 patients. Health Aff (Millwood). 2012;31(2):383-91. Epub 2012/02/11. doi:
- 954 10.1377/hlthaff.2010.1137. PubMed PMID: 22323169.
- 955 83. Saito S, Maeno T, Miyata Y, Maeno T. Follow-up survey of Japanese
- 956 medical students' interactions with the pharmaceutical industry. PLOS ONE.
- 957 2018;13(11):e0206543. doi: 10.1371/journal.pone.0206543.
- 958 84. Montastruc F, Moulis G, Palmaro A, Gardette V, Durrieu G,
- 959 Montastruc J-L. Interactions between medical residents and drug companies:
- 960 a national survey after the Mediator® affair. PLoS One. 2014;9(10):e104828.
- 961 85. Hodges B. Interactions with the pharmaceutical industry:
- 962 experiences and attitudes of psychiatry residents, interns and clerks. Cmaj.
- 963 1995;153(5):553-9. Epub 1995/09/01. PubMed PMID: 7641153; PubMed Central
- 964 PMCID: PMCPMC1487391.
- 965 86. Inoue K, Figueroa JF, Orav EJ, Tsugawa Y. Association between
- 966 industry payments for opioid products and physicians' prescription of
- 967 opioids: observational study with propensity-score matching. Journal of
- 968 Epidemiology and Community Health. 2020;74(8):647-54. doi:
- 969 10.1136/jech-2020-214021.
- 970 87. Civaner MM. A follow-up study on the effects of an educational
- 971 intervention against pharmaceutical promotion. PLOS ONE.
- 972 2020;15 (10):e0240713. doi: 10.1371/journal.pone.0240713.
- 973 88. Austad KE, Avorn J, Kesselheim AS. Medical Students' Exposure to
- 974 and Attitudes about the Pharmaceutical Industry: A Systematic Review. PLOS
- 975 Medicine. 2011;8(5):e1001037. doi: 10.1371/journal.pmed.1001037.

978 Acknowledgement

976

979 Authors appreciate Dr. Derek Hagman for professional English language editing and 980 constructive opinions for this study. 981 982 **Author contributions** 983 We describe contributions to the paper using the CRediT taxonomy provided above. 984 Conceptualization: all authors; 985 Data curation: A.M.; 986 Formal analysis: A.M.; 987 Funding acquisition: A.O.; 988 Investigation: all authors; Methodology: all authors; 989 Project Administration: A.O., and T.T.; 990 Supervision: A.O., and T.T; 991 Visualization: A.M., A.O., and T.T.; 992 Writing – Original Draft: Y.S., A.M., K.H.; 993 Writing – review & editing: A.M., Y.K., T.T., and A.O. 994 All authors revised the manuscript critically for important intellectual content, gave final approval of the revision to be published, and agreed to be accountable for all the aspects of the study. **Conflicts of interest** Dr. Saito receives personal fees from Taiho Pharmaceutical Co., Ltd. outside the scope of the submitted work. Dr. Ozaki receives personal fees from Medical Network Systems outside the scope of the submitted work. Dr. Tanimoto receives personal fees from Medical Network Systems and Bionics Co. Ltd. outside the scope of the submitted work. The remaining authors declare no financial conflicts of interest. Anju Murayama, Yuki Senoo, Kayo Harada, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto, and Akihiko Ozaki report a number of studies on conflicts of interest in Japan. **Funding** This study was funded in part by the Medical Governance Research Institute. This non-profit enterprise receives donations from pharmaceutical companies, including Ain Pharmaciez, Inc., other organizations, and private individuals. This study also received

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

support from the Tansa (formerly known as Waseda Chronicle), an independent non-profit news organization dedicated to investigative journalism. Ain Pharmacies had no role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, the preparation, review, and approval of the manuscript, or the decision to submit the manuscript for publication. Tansa was engaged in the collection and management of the payment data, but had no role in the design and conduct of the study, the analysis and interpretation of the data, the preparation, review and approval of the manuscript, or the decision to submit the manuscript for publication. **Supporting information: Supplementary Method Variables** Sociodemographic factors. Sociodemographic factors included age, sex, highest educational attainment (less than high school graduate; high school graduate; associate degree or diploma; or bachelor's degree or more), employment status (full time job; self-employed; part-time job; unemployed; or other), and annual income (<2 million JPY (<18,349 USD); 2-4 million JPY (18,349-36,697 USD); 4-6 million JPY (36,697-55,046 USD); 6-8 million JPY (55,046-73,394 USD); 8-10 million JPY (73,394-91,743 USD); or >10 million JPY (>91,743 USD). Primary diagnosis. We asked participant's primary disease and categorized it into seven types: non-cancer, prostate cancer, lung cancer, breast cancer, colorectal cancer, gastric cancer, and other kinds of cancer. Clinical factors relating to cancer (only for cancer patients). For cancer patients, we collected data on

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

10291030

1031

clinical characteristics including disease stage (Stage II, Stage III, Stage III, Stage IV, or unclear), year of diagnosis (2018, 2017, 2016, 2015, or before 2015), type of hospital in which participant received treatment (Cancer hospital, national university hospital, private university hospital, national municipal hospital, private municipal hospital, or other hospital), the treatment participants had been receiving (no active treatment, anticancer drug, molecularly targeted drug, immune checkpoint inhibitor, hormonal therapy, radiation therapy, or other therapy), treatments participants had ever received (no active treatment, anticancer drug, molecularly targeted drug, immune checkpoint inhibitor, hormonal therapy, radiation therapy, surgery, or other therapy), and disease recurrence (yes, no, not clear, or other). Awareness of physician-Pharma interactions. To assess awareness of physician-Pharma interactions, we evaluated awareness of 11 types of interactions, including pamphlets and leaflets, stationeries, textbooks and articles, free drug samples, free meals travel and accommodations, lecture fees, disclosure program of the payment from Pharma to physicians, conduct of research for Pharma, outsourcing expenses, and possession of stocks. Consequently, we used the following question, "Do you know that some physicians would receive pamphlet and leaflet concerning products manufactured by pharmaceutical companies from their sales representatives?" on a three-point Likert scale (Yes, No, or Not sure). Other items are listed in Supplementary Material 2. *Influence on trust in physicians.* We assessed the impact on trust in physicians over 11 types of interactions including, pamphlets and leaflets, stationeries, textbooks and articles, free drug samples, free meals, travel and accommodations, lecture fees, conduct of research for Pharma, outsourcing expenses, possession of stocks, and insider trading. Consequently, we used the following question, "How would your trust in your physician be influenced if your physician received pamphlet or leaflet with information about the products from a pharmaceutical sales representative?" on a five-point Likert scale (Increase of trust in physicians, Slight increase of trust in physicians, Neither increase nor decrease of trust in physicians, Slight decrease of trust in physicians, or Decrease of trust in physicians). Other items are listed in Supplementary Material 3. Perception on physician-Pharma interaction. We evaluated participants' perception of physician-Pharma interactions by assessing whether to agree with the following statements. 1) "Payments from pharmaceutical companies would influence physician prescription pattern." 2) "Payments from pharmaceutical companies would increase unnecessary prescriptions and healthcare costs." 3) "A receipt of payments from pharmaceutical companies would be acceptable as long as its amount is small." 4)

1034

1035

1036

1037

1038

1039

1040

1041

10421043

1044

1045

1046

1047

1048

1049

1050

10511052

1053

1054

1055

1056

1057

1058

1059

1060

1061 1062

1063

1064

1065

"Physician's receipts of gifts, meals and honoraria from pharmaceutical companies are unethical." 5) "Physician's receipts of gifts, meals, and honoraria from pharmaceutical companies would undermine the trust in physicians." 6) "More rigorous internal regulation of gifts, meals, and honoraria from pharmaceutical companies to physicians is needed among pharmaceutical companies." 7) "More rigorous internal regulation of gifts, meals, and honoraria from pharmaceutical companies to physicians is needed among physicians." 8) "More rigorous legal regulation of gifts, meals, and honoraria from pharmaceutical companies to physicians is needed." On a five-point Likert scale (Agree, Slightly agree, Neither agree nor disagree, Slightly disagree, or Disagree). Further, for participants who agree or slightly agree with the third statement, we additionally asked the closet amount of money which they think is acceptable on a four-point scale (1,000 JPY (9.2 USD) or below, 1,000-3,000 JPY (9.2-27.5 USD), 3,000-10,000 JPY (27.5-91.7 USD), or other). For participants who agreed or slightly agreed with either of sixth, seventh or eighth statement, we additionally asked the monetary value (100 thousand JPY (917 USD) or below, 100 thousand-1 million JPY (917-9174 USD), 1-5 million JPY (9,174-45,872 USD), 5-10 million JPY (45,872-91,743 USD, or 10-30 million JPY (91,743-275,229 USD)) and frequency (twice a week, once a week, once every two weeks, once a month, or once every few months) of the financial interaction with the Pharma. (Supplementary Material 4) Attitude towards various professional FCOI was assessed by using the following five statements. 1) "It is problematic for judges to receive gifts, meals, and other entertainment from the trial attorney in charge." 2) "It is problematic for sports referees to receive gifts, meals, and other entertainment from the players of the games they are assigned to." 3) "It is problematic for politicians to receive gifts, meals, and other entertainment from lobbyists." 4) "It is problematic for physicians to receive gifts, meals, and other entertainment from pharmaceutical sales representatives." 5) "It is problematic for business people to receive gifts, meals, and other entertainment from their customers." On a five-point Likert scale (Agree, Slightly agree, Neither agree nor disagree, Slightly disagree, or Disagree). An open-ended question about participants' perception of FCOI between Pharma and physicians. To dig deeper into participants' perceptions on FCOI between Pharma and physicians, we investigated responses to an open-ended question: "Please freely describe your thoughts about non-research-related offerings from Pharma to a physician (e.g., gifts, free meals, monetary incentives for a lecture)." The responses to this question were analyzed separately through qualitative analysis.

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

10831084

1085

1086

1087

1088

1089

1090

1091

1092

10931094


1095


1096

1097


1098


Supplementary Material 2. List of questions regarding awareness of physician-Pharma interactions. Supplementary Material 3. List of questions regarding influence on trust in physicians. Supplementary Material 4. List of questions regarding perception on physician-Pharma interactions. Supplementary Material 5. Demographic breakdown on the number and percent of participants who were aware of at least one physician-Pharma interaction. ¹The analysis included only participants with cancer. Abbreviations: JPY; Japanese yen, USD; US dollar, Pharma; Pharmaceutical Company. Supplementary Material 6. Logistic regression analysis of participants' awareness of physician-Pharma interactions. ¹The analysis included only participants with cancer. Abbreviations: JPY; Japanese yen, Pharma; Pharmaceutical Company, Ref; reference value. Supplementary Material 7. Number and percent of participants who reported decreased trust in at least one physician-Pharma interaction by participant demographics. ¹The analysis included only participants with cancer. Abbreviations: JPY; Japanese yen, Pharma; Pharmaceutical Company. Supplementary Material 8. Logistic regression analysis of the influence of physician-Pharma relationships on participants' trust. ¹ The analysis included only participants with cancer. There were no statistically significant differences between the influence of physician-pharmaceutical company relationships on participants' trust and each variable. Abbreviations: JPY; Japanese yen, Pharma; Pharmaceutical Company.






- 1) Payments from pharmaceutical companies would influence physician prescription pattern.
- 2) Payments from pharmaceutical companies would increase unnecessary prescriptions and healthcare cost.
- A receipt of payments from pharmaceutical companies would be acceptable as long as its amount is small.
- 4) Physician's receipts of gifts, meals and honoraria from pharmaceutical companies are unethical.
- Physician's receipts of gifts, meals and honoraria from pharmaceutical companies would undermine the trust in physicians.
- More rigorous internal regulation of gifts, meals, and honoraria from pharmaceutical companies to physicians is needed among pharmaceutical companies.
- More rigorous internal regulation of gifts, meals, and honoraria from pharmaceutical companies to physicians is needed among physicians.
- More rigorous legal regulation of gifts, meals, and honoraria from pharmaceutical companies to physicians is needed.






Disagree

Slightly disagree





- It is problematic for sport referees to receive gifts, meal, and other entertainment from the players of the games they are assigned to.
- It is problematic for politicians to receive gifts, meals, and other entertainment from lobbyists.
- It is problematic for physicians to receive gifts, meals, and other entertainment from pharmaceutical sales representatives.
- It is problematic for business people to receive gifts, meals, and other entertainment from their customers.

